Eli Lilly and Company $LLY Holdings Lifted by Veracity Capital LLC

Veracity Capital LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 52.2% during the third quarter, HoldingsChannel.com reports. The firm owned 2,850 shares of the company’s stock after acquiring an additional 978 shares during the period. Eli Lilly and Company comprises approximately 0.9% of Veracity Capital LLC’s holdings, making the stock its 16th biggest holding. Veracity Capital LLC’s holdings in Eli Lilly and Company were worth $3,298,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Coastal Bridge Advisors LLC bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $2,959,000. Mosaic Family Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after acquiring an additional 1,430 shares during the last quarter. Moran Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 85.6% in the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after acquiring an additional 9,638 shares in the last quarter. Generali Investments Management Co LLC lifted its holdings in Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Amundi grew its holdings in Eli Lilly and Company by 9.9% during the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by corporate insiders.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside based on expectations for continued earnings and pipeline growth.
• Positive Sentiment: Obesity pipeline remains a major catalyst: Analysts point to retatrutide, Lilly’s next-generation triple-hormone weight-loss candidate, as a potential successor to Mounjaro and Zepbound. Its reported clinical weight-loss results and potential applications in related conditions could expand Lilly’s long-term addressable market. Eli Lilly’s Obesity Business Could Become a Much Bigger Healthcare Platform
• Positive Sentiment: Pipeline diversification continues: Lilly is testing eloralintide in an obesity-related study involving hormonal contraception and has initiated an early-stage Alzheimer’s trial. These studies are preliminary, but they reinforce the company’s efforts to build growth beyond its current GLP-1 franchise. Eli Lilly Tests Obesity Drug Eloralintide With Birth Control
• Positive Sentiment: Oncology and technical support: Jaypirca, Inluriyo and Retevmo could help offset slowing Verzenio sales, while a move above the 50-day moving average is viewed by some technical analysts as a short-term bullish signal.
• Neutral Sentiment: Investor sentiment remains constructive: Commentary highlights Lilly’s “growth flywheel” from GLP-1 demand, manufacturing expansion, new indications and earnings growth. However, these are largely forward-looking investment opinions rather than new financial results.
• Negative Sentiment: Valuation and competition remain concerns: Lilly trades at a premium multiple, leaving the stock vulnerable to profit-taking if obesity-drug growth slows, pricing pressure increases or Novo Nordisk and other competitors gain share. LLY Stock Down 2% in 3 Months
• Negative Sentiment: New obesity guidelines could create uncertainty: The World Health Organization’s childhood-obesity recommendations may increase scrutiny of how weight-loss medicines are used in younger populations, potentially affecting future market expectations for Lilly and Novo Nordisk.

Eli Lilly and Company Stock Down 3.2%

Shares of NYSE LLY traded down $38.03 during mid-day trading on Thursday, reaching $1,150.69. The company had a trading volume of 1,719,061 shares, compared to its average volume of 2,967,456. Eli Lilly and Company has a twelve month low of $783.85 and a twelve month high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a market capitalization of $1.08 trillion, a PE ratio of 38.63, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46. The stock’s 50 day moving average is $1,173.51 and its 200-day moving average is $1,094.59.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter last year, the firm earned $6.31 earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Guggenheim upped their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Finally, Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.